Clinical Research Directory
Browse clinical research sites, groups, and studies.
Kisspeptin Administration Subcutaneously to Patients With IHH
Sponsor: Stephanie B. Seminara, MD
Summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. Funding Source: FDA OOPD
Official title: Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2023-02-03
Completion Date
2028-05
Last Updated
2025-10-03
Healthy Volunteers
No
Conditions
Interventions
kisspeptin 112-121
SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
leuprolide acetate
Single SC bolus
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States